<DOC>
	<DOCNO>NCT00934739</DOCNO>
	<brief_summary>Objectives : 1 . To study effect anti-angiogenesis therapy reduce recurrence high-risk oral cavity cancer patient curative local treatment . 2 . To study toxicity compliance post-operative anti-angiogenesis therapy Study design : This multi-center randomize controlled phase II/III two-stage study . Study endpoint : The primary endpoint tumor-free survival ( primary second primary malignancy ) primary analysis compare tumor-free survival group .</brief_summary>
	<brief_title>A Study High-Risk Oral Cavity Cancer</brief_title>
	<detailed_description>Type number patient : Patients resectable oral cancer clinical stage N2 , 3 skin-involved T4 enrol . Sample size first stage 64 patient per group total sample size end second stage 192 patient per group , assume accrual rate/hazard rate = 1.33 , α=0.05 power 0.8 ( Hypotheses : H0 : θ ≦ 1.0 Ha : θ ≧ 1.33 ) Treatment schedule : Group A：standard postoperative concurrent chemoradiotherapy . Group B：Immediately operation start thalidomide ( 50 ) 4 # per day celecoxib ( 200 ) 2 # bid three week , addition standard postoperative concurrent chemoradiotherapy . Group C：Immediately operation start cyclophosphamide ( 50 ) 1 # per day dexamethasone ( 0.5 ) 2 # qd three week , addition standard postoperative concurrent chemoradiotherapy .</detailed_description>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Histologically proved oral cavity squamous cell carcinoma ( buccal mobile tongue ) . 2 . Clinical stage T4a skin involvement resectable N23 UICC/AJCC 1997 stag system . ( 24 ) 3 . Curativeintent operation feasible arrange . 4 . Eastern Cooperative Oncology Group performance status ≦ 1 . 5 . A leukocyte count ≧3750/μL , Hb ≧10 g/dL , platelet count ≧100,000/μL . 6 . A serum bilirubin level &lt; 1.5 UNL ( upper normal limit ) , serum creatinine level &lt; 1.5 UNL creatinine clearance &gt; 60 mL/min . 7 . Age le 70 year old 8 . Informed consent sign . 1 . Evidence distant metastatic . 2 . Presence another malignancy treat squamous/basal cell carcinoma skin . 3 . Presence uncontrolled hypertension , poorly control heart failure . 4 . Presence active infection . 5 . Patients treat chemotherapy , radiotherapy , immunotherapy , experimental therapy . 6 . Women test positive pregnancy . Note : Patients receive neck lymph node biopsy eligible stage give accord preoperative status .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>High-Risk Oral Cavity Cancer ,</keyword>
	<keyword>Anti-Angiogenesis</keyword>
</DOC>